AstraZeneca (AZN-0.67%) hopes to soon close its planned acquisition of Alexion Pharmaceuticals . The only hurdle left to jump is obtaining approval from United Kingdom regulators.

Drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid-19 pandemic.

Under the terms of the deal, AstraZeneca will pay $60 in cash and 2.1243 of its American depositary receipts for each of Alexion’s shares. That amounts to $175 a share, a nearly 45 percent ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...

Just as any takeover target would, Alexion asked AstraZeneca to increase its buyout offer several times before the two shook hands on the $39 billion deal unveiled in December.

Britain's AstraZeneca (AZN.L) has agreed to buy U.S. drugmaker Alexion Pharmaceuticals (ALXN.O) for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in ...

The transaction values Alexion at $175 per share, a sizeable 45% premium on its closing price on Friday, the day before the deal was announced. Alexion shareholders will receive $60 in cash, plus ...

11 January 2022 Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune ...

In yet another announcement this morning, AstraZeneca revealed that Alexion has agreed a deal worth “up to $1 billion” for “a portfolio of preclinical gene therapy programs and enabling ...

AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). The only hurdle left to jump is obtaining approval from United Kingdom regulators.

We’ll send you a myFT Daily Digest email rounding up the latest Mergers & Acquisitions news every morning. Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in ...

Anglo-Swedish drugmaker AstraZeneca has agreed to buy US biotechnology group Alexion in a $39bn deal, marking the biggest agreement struck by a pharmaceutical company since the start of the Covid ...